Study of Pembrolizumab Plus Trastuzumab or Trastuzumab Alone After Surgery in Patients With Esophagogastric Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Cancer
- Esophageal Neoplasms
- Esophageal Tumor
- Esophagogastric Tumors
- Gastric Cancer
- Gastric Tumor
- Gastroesophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction Cancer
- Gastroesophageal Junction Tumor
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Care Provider)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04510285
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Yelena Y Janjigian, MD Memorial Sloan Kettering Cancer Center
Get Well Soon